|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
199.88 USD |
+1.66% | -2.83% | -11.90% | |
April 23, 2025 at 08:27 am EDT
© MT Newswires – 2025
|
Becton, Dickinson and Co Launches Umbilical Hernia Patch After FDA Clearance |
08:27am |
MT |
|
BD Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair |
07:02am |
RE |
|
Becton, Dickinson and Company Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair |
06:50am |
CI |
|
Becton, Dickinson and Company Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with Ai-Driven Clinical Decision Support |
Apr. 21 |
CI |
|
Citigroup Adjusts Becton Dickinson and Co. Price Target to $270 From $275, Maintains Buy Rating |
Apr. 07 |
MT |
|
Barclays Adjusts PT on Becton Dickinson and Co. to $261 From $279, Keeps Overweight Rating |
Apr. 07 |
MT |
|
PRESS DIGEST- Financial Times – April 2 |
Apr. 01 |
RE |
|
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports |
Apr. 01 |
RE |
|
Becton Dickinson in talks to divest life sciences unit, FT reports |
Apr. 01 |
RE |
|
Becton Dickinson In Talks With Rivals Over Divesting Life Sciences Unit- FT |
Apr. 01 |
RE |
|
BD Names Gregory J. Hayes To Board Of Directors |
Mar. 27 |
RE |
|
Becton, Dickinson and Company Appoints Gregory J. Hayes to Board of Directors, Effective March 26, 2025 |
Mar. 27 |
CI |
|
Goldman Sachs Adjusts PT on Becton Dickinson and Co. to $256 From $253, Keeps Buy Rating |
Mar. 27 |
MT |
|
FDA Says Bard Peripheral Vascular Issued Letter To Affected Customers On Rotarex Atherectomy Systems Usage |
Mar. 20 |
RE |
|
Becton, Dickinson Treats First Breast Revision Patient in GalaFlex Lite Scaffold Trial |
Mar. 20 |
MT |
|
Becton, Dickinson and Company Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE? Scaffold in Breast Implant Revision Surgery |
Mar. 20 |
CI |
|
Becton Dickinson & Co Insider Sold Shares Worth $436,325, According to a Recent SEC Filing |
Mar. 13 |
MT |
|
Becton, Dickinson and Company Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-11-2025 08:30 AM |
Mar. 11 |
|
|
Becton, Dickinson and Company Presents at Citi?s 2025 Unplugged Medtech and Life Sciences Access Day, Feb-27-2025 08:45 AM |
Feb. 27 |
|
|
Argus Adjusts Becton Dickinson and Co.’s Price Target to $270 From $290 |
Feb. 21 |
MT |
|
Barclays Adjusts Price Target on Becton, Dickinson and Company to $279 From $278 |
Feb. 14 |
MT |
|
Becton Dickinson & Insider Bought Shares Worth $350,430, According to a Recent SEC Filing |
Feb. 10 |
MT |
|
Wells Fargo Adjusts Becton, Dickinson Price Target to $270 From $275 |
Feb. 06 |
MT |
|
Becton, Dickinson and Company, Q1 2025 Earnings Call, Feb 06, 2025 |
Feb. 06 |
|
|
Stocks Mostly Up Pre-Bell Ahead of Latest Earnings; Asia, Europe Strong |
Feb. 06 |
MT |
BDX: Dynamic Chart
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
– medical management systems (49.8%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.;
– diagnostic materials and clinical research and development tools (25.6%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc.;
– interventional medical equipment (24.6%): surgical instruments, urological care products, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
More about the company
Buy
Last Close Price
199.88USD
Average target price
273.70USD
Spread / Average Target
+36.93%
Consensus
